United States: How Will The Supreme Court Choreograph The Biosimilar Patent Dance?

On April 26, 2017, the Supreme Court heard oral arguments in Amgen v. Sandoz, where the parties have asked the Court to interpret two of the biosimilar patent dance provisions of the Biologics Price Competition and Innovation Act (BPCIA). While it is never wise to predict how the Justices will rule based on the questions and comments at oral hearing, I would not be surprised if they uphold the Federal Circuit's interpretation of this complicated statute.

The Questions Presented

As summarized in this article, there are two issues of statutory construction before the Court:

  1. Can the notice of commercial marketing required by 42 U.S.C. § 262(l)(8)(A) be given before the FDA has approved the biosimilar product? (The Federal Circuit said no; Sandoz urges yes)
  2. Do biosimilar applicants have to share their biosimilar application and other information in accordance with 42 U.S.C. § 262(l)(2)(A)? (The Federal Circuit said no; Amgen urges yes)

Although the Solicitor General of the United States filed an amicus brief that sided with Sandoz on both issues, the Justices seemed inclined to affirm the Federal Circuit on both issues.

What Would You "Notice" Prior To Approval?

The Justices who commented on this issue seemed to agree with the Federal Circuit that the notice of commercial marketing required by 42 U.S.C. § 262(l)(8)(A) cannot be given until the FDA has approved the biosimilar product—otherwise what would you be giving notice of?

Justice Breyer: What does this notice say? And what it says is that you have to provide ... notice of ... first commercial marketing of the biological product licensed. .... Now, how could you do that if you don't know what the product licensed is?

Once this notice has been given, the Reference Product Sponsor has an opportunity to assert any remaining patents. Thus, the Justices asked how the Reference Product Sponsor would know which patents could be asserted if the biosimilar product had not yet been approved. Sandoz's attorney argued that the very nature of a biosimilar product would provide such information:

Ms. Maynard: By definition, a biosimilar is highly similar to the reference-product sponsor's product. So a reference-product sponsor would have good-faith basis in that case to bring suit on any patent that covers its own product, or any patent that covers a use of its own product.

Chief Justice Roberts wasn't entirely convinced:

CHIEF JUSTICE ROBERTS: But it doesn't know the specifics of the biosimilar. I mean, by definition, the biosimilar is similar; it's not identical. And whether or not it infringes might have something to do with the ways in which it is different.

On the other hand, Justice Kagan pointed out that the "patent dance" litigation is based on the biosimilar application, and so would suffer from the same uncertainty vis-a-vis any changes embodied in the approved product:

JUSTICE KAGAN: But isn't that true of a lot of what this Act contemplates? I mean, all the round 1 litigation can occur before the approval is given.

Should Reference Product Sponsors Have 12.5 Years Exclusivity?

None of the Justices seemed comfortable with the consequence of requiring approval prior to notice, i.e., effectively providing the original biologic product with an additional 180 days of market exclusivity. There was some discussion of whether the FDA might be able to approve or signal approval of a biosimilar product before the 12 year period had run (but only make the approval effective at 12 years), but as I wrote in this article it is not clear that the FDA would or could do so.

What About The Biosimilar Patent Dance?

Although Amgen had framed the "patent dance" issue as whether "shall" means "shall," the Justices focused on the statutory consequences for violating the "shall" requirement. On this issue, they seemed to agree that the only remedy available to a Reference Product Sponsor if the biosimilar application does not provide the information required by § 262(l)(2)(A) is to bring a declaratory judgment action under § 262(l)(9)(C):

GORSUCH: Mr. Waxman, let's say -let's say I spot you that, okay, that (2)(A) "shall" means shall. .... And how can we possibly decide what (2)(A) means without taking a peek at (9)(C) as to what remedies are permitted? .... You can't –it's hard to divorce a right from its remedy, isn't it, and to understand the contours of the right. And if (2)(A) gives you a certain right to information, we usually understand the right in the context of the remedy provided. .... And here the remedy is (9)(C).

Justice Sotomayor read the statutory scheme differently, as presenting two options for resolving patent disputes:

JUSTICE SOTOMAYOR: "Shall" is if you want to invoke this Federal process [the patent dance], this is what you have to do. .... So if you don't invoke the Federal process, what remains? That's not a remedy. That's a different Federal process, the declaratory-judgment process. That's what (C) says.

Were Amgen's State Law Claims Preempted?

Although neither party had briefed the issue, the Justices asked both parties about preemption of the state law claims that Amgen had asserted against Sandoz. Arguing for the United States, the Assistant to the Solicitor General came the closest to taking a position on this issue:

MR. YANG: I think there are strong arguments that this would be preempted. This is a highly detailed scheme. And if States were to start to interject different means of enforcing it on a State-by-State basis, that might wreak some havoc, but we've not taken a position on that.

Why Hasn't An Agency Interpreted These Provisions

One interesting theme in the Justices' questions was their wondering why an agency (the FDA or PTO) had not weighed in on these issues in the first instance.

JUSTICE BREYER: Now, we are being asked to interpret very technical provisions that I find somewhat ambiguous and am operating in a field I know nothing about. But it's going to have huge implications for the future. So why isn't the way to go about this case to ask the agency to issue some regulations? Then when we see their interpretation, you all will be able to argue that their interpretation exceeds the statutory delegation. And by doing that, we would have a better picture.

However, since neither the FDA nor the USPTO oversee the patent dance, it will be up to the Court to interpret these biosimilar patent dance provisions.

Read More About This Biosimilar Dispute

These articles discuss previous proceedings in Amgen v. Sandoz and explain the biosimilar patent dance issues in more detail:

If the Court follows its usual schedule, a decision will be rendered by the end of the Court's current term in June.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.